Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis.

[1]  P. Keith,et al.  2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema , 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

[2]  A. Kaplan,et al.  Factor XII-independent cleavage of high-molecular-weight kininogen by prekallikrein and inhibition by C1 inhibitor. , 2009, Journal of Allergy and Clinical Immunology.

[3]  B. Zuraw.  Clinical practice. Hereditary angioedema. , 2008, The New England journal of medicine.

[4]  A. Kaplan,et al.  Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. , 2008, Annals of Allergy, Asthma & Immunology.

[5]  P. Schlattmann,et al.  Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). , 2007, The Journal of allergy and clinical immunology.

[6]  M. Cicardi,et al.  Anaphylaxis in Response to C1 Esterase Inhibitor in a Patient with Hereditary Angioedema , 2007 .

[7]  M. Frank.  Hereditary angioedema: the clinical syndrome and its management in the United States. , 2006, Immunology and allergy clinics of North America.

[8]  William H. Yang,et al.  Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema. , 2004, The Journal of allergy and clinical immunology.

[9]  A. Tordai,et al.  Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond , 2004, Journal of Allergy and Clinical Immunology.

[10]  P. Patston,et al.  The reaction between plasmin and C1-inhibitor results in plasmin inhibition by the serpin mechanism , 2002, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[11]  M. Silverberg,et al.  Pathways for bradykinin formation and inflammatory disease. , 2002, The Journal of allergy and clinical immunology.

[12]  B. Zuraw,et al.  Detection of C1 inhibitor mutations in patients with hereditary angioedema. , 2000, The Journal of allergy and clinical immunology.

[13]  M. Cicardi,et al.  Local bradykinin generation in hereditary angioedema. , 1999, The Journal of allergy and clinical immunology.

[14]  M. Tosi.  Molecular genetics of C1 inhibitor. , 1998, Immunobiology.

[15]  J. Karsh,et al.  C1-esterase inhibitor transfusions in patients with hereditary angioedema. , 1998, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[16]  C. Feighery,et al.  Degradation of C1-Inhibitor by Plasmin: Implications for the Control of Inflammatory Processes , 1997, Molecular medicine.

[17]  M. Cicardi,et al.  Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. , 1996, Immunopharmacology.

[18]  A. Davis,et al.  Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability‐enhancing activities , 1994, Clinical and experimental immunology.

[19]  A. Eerenberg,et al.  Generation of plasmin during acute attacks of hereditary angioedema. , 1993, The Journal of laboratory and clinical medicine.

[20]  V. Donaldson,et al.  Comparison of human high molecular weight kininogen digestion by plasma kallikrein and by plasmin. A revised method of purification of high molecular weight kininogen. , 1987, The Journal of laboratory and clinical medicine.

[21]  M. Silverberg,et al.  The effect of C1 inhibitor upon Hageman factor autoactivation. , 1986, Blood.

[22]  K. Fujikawa,et al.  The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. , 1986, The Journal of biological chemistry.

[23]  M. Gilbert,et al.  Tissue plasminogen activator release in vivo in response to vasoactive agents. , 1985, Blood.

[24]  A. Kaplan,et al.  Distribution of plasma kallikrein between C-1 inactivator and alpha 2-macroglobulin in plasma utilizing a new assay for alpha 2-macroglobulin-kallikrein complexes. , 1985, The Journal of biological chemistry.

[25]  R. Colman,et al.  The regulation of human factor XIIa by plasma proteinase inhibitors. , 1985, The Journal of biological chemistry.

[26]  A. Kaplan,et al.  Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. , 1983, The Journal of allergy and clinical immunology.

[27]  R. Colman,et al.  Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. , 1983, The New England journal of medicine.

[28]  J. Dunn,et al.  Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. , 1983, The Journal of clinical investigation.

[29]  A. Sheffer,et al.  Clinical and biochemical effects of stanozolol therapy for hereditary angioedema. , 1981, The Journal of allergy and clinical immunology.

[30]  M. Silverberg,et al.  Activation of the classical pathway of complement by Hageman factor fragment , 1981, The Journal of experimental medicine.

[31]  J. Gelfand,et al.  Replacement therapy in hereditary angioedema: successful treatment of acute episodes of angioedema with partly purified C1 inhibitor. , 1980, The New England journal of medicine.

[32]  A. Kaplan,et al.  Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis. , 1977, The Journal of biological chemistry.

[33]  D. Alling,et al.  Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. , 1976, The New England journal of medicine.

[34]  I. Clemmensen,et al.  The primary inhibitor of plasmin in human plasma. , 1976, The Biochemical journal.

[35]  K.,et al.  Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. , 1973, The Journal of clinical investigation.

[36]  A. Sheffer,et al.  Tranexamic acid therapy in hereditary angioneurotic edema. , 1972, The New England journal of medicine.

[37]  D. Alling,et al.  Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. , 1972, The New England journal of medicine.

[38]  K. Austen,et al.  A PREALBUMIN ACTIVATOR OF PREKALLIKREIN , 1971, The Journal of experimental medicine.